University of Leicester
Browse
1-s2.0-S014067361830134X-main.pdf (594.24 kB)

Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies.

Download (594.24 kB)
journal contribution
posted on 2018-08-13, 15:26 authored by AM Wood, S Kaptoge, AS Butterworth, P Willeit, S Warnakula, T Bolton, E Paige, DS Paul, M Sweeting, S Burgess, S Bell, W Astle, D Stevens, A Koulman, RM Selmer, WMM Verschuren, S Sato, I Njølstad, M Woodward, V Salomaa, BG Nordestgaard, BB Yeap, A Fletcher, O Melander, LH Kuller, B Balkau, M Marmot, W Koenig, E Casiglia, C Cooper, V Arndt, OH Franco, P Wennberg, J Gallacher, AG de la Cámara, H Völzke, CC Dahm, CE Dale, MM Bergmann, CJ Crespo, YT van der Schouw, R Kaaks, LA Simons, P Lagiou, JD Schoufour, JMA Boer, TJ Key, B Rodriguez, C Moreno-Iribas, KW Davidson, JO Taylor, C Sacerdote, RB Wallace, JR Quiros, R Tumino, DG Blazer, A Linneberg, M Daimon, S Panico, B Howard, G Skeie, T Strandberg, E Weiderpass, PJ Nietert, BM Psaty, D Kromhout, E Salamanca-Fernandez, S Kiechl, HM Krumholz, S Grioni, D Palli, JM Huerta, J Price, J Sundström, L Arriola, H Arima, RC Travis, DB Panagiotakos, A Karakatsani, A Trichopoulou, T Kühn, DE Grobbee, E Barrett-Connor, N van Schoor, H Boeing, K Overvad, J Kauhanen, N Wareham, C Langenberg, N Forouhi, M Wennberg, J-P Després, M Cushman, JA Cooper, CJ Rodriguez, M Sakurai, JE Shaw, M Knuiman, T Voortman, C Meisinger, A Tjønneland, H Brenner, L Palmieri, J Dallongeville, EJ Brunner, G Assmann, M Trevisan, RF Gillum, I Ford, N Sattar, M Lazo, SG Thompson, P Ferrari, DA Leon, GD Smith, R Peto, R Jackson, E Banks, E Di Angelantonio, J Danesh, Emerging Risk Factors Collaboration/EPIC-CVD/UK Biobank Alcohol Study Group
BACKGROUND: Low-risk limits recommended for alcohol consumption vary substantially across different national guidelines. To define thresholds associated with lowest risk for all-cause mortality and cardiovascular disease, we studied individual-participant data from 599 912 current drinkers without previous cardiovascular disease. METHODS: We did a combined analysis of individual-participant data from three large-scale data sources in 19 high-income countries (the Emerging Risk Factors Collaboration, EPIC-CVD, and the UK Biobank). We characterised dose-response associations and calculated hazard ratios (HRs) per 100 g per week of alcohol (12·5 units per week) across 83 prospective studies, adjusting at least for study or centre, age, sex, smoking, and diabetes. To be eligible for the analysis, participants had to have information recorded about their alcohol consumption amount and status (ie, non-drinker vs current drinker), plus age, sex, history of diabetes and smoking status, at least 1 year of follow-up after baseline, and no baseline history of cardiovascular disease. The main analyses focused on current drinkers, whose baseline alcohol consumption was categorised into eight predefined groups according to the amount in grams consumed per week. We assessed alcohol consumption in relation to all-cause mortality, total cardiovascular disease, and several cardiovascular disease subtypes. We corrected HRs for estimated long-term variability in alcohol consumption using 152 640 serial alcohol assessments obtained some years apart (median interval 5·6 years [5th-95th percentile 1·04-13·5]) from 71 011 participants from 37 studies. FINDINGS: In the 599 912 current drinkers included in the analysis, we recorded 40 310 deaths and 39 018 incident cardiovascular disease events during 5·4 million person-years of follow-up. For all-cause mortality, we recorded a positive and curvilinear association with the level of alcohol consumption, with the minimum mortality risk around or below 100 g per week. Alcohol consumption was roughly linearly associated with a higher risk of stroke (HR per 100 g per week higher consumption 1·14, 95% CI, 1·10-1·17), coronary disease excluding myocardial infarction (1·06, 1·00-1·11), heart failure (1·09, 1·03-1·15), fatal hypertensive disease (1·24, 1·15-1·33); and fatal aortic aneurysm (1·15, 1·03-1·28). By contrast, increased alcohol consumption was log-linearly associated with a lower risk of myocardial infarction (HR 0·94, 0·91-0·97). In comparison to those who reported drinking >0-≤100 g per week, those who reported drinking >100-≤200 g per week, >200-≤350 g per week, or >350 g per week had lower life expectancy at age 40 years of approximately 6 months, 1-2 years, or 4-5 years, respectively. INTERPRETATION: In current drinkers of alcohol in high-income countries, the threshold for lowest risk of all-cause mortality was about 100 g/week. For cardiovascular disease subtypes other than myocardial infarction, there were no clear risk thresholds below which lower alcohol consumption stopped being associated with lower disease risk. These data support limits for alcohol consumption that are lower than those recommended in most current guidelines. FUNDING: UK Medical Research Council, British Heart Foundation, National Institute for Health Research, European Union Framework 7, and European Research Council.

Funding

The study's coordinating centre (Emerging Risk Factors Collaboration and EPIC-CVD Coordinating Centres, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK) has been underpinned by grants from the UK Medical Research Council (G0800270 and MR/L003120/1), British Heart Foundation (SP/09/002, RG/08/014 and RG13/13/30194), National Institute for Health Research (through the National Institute for Health Research Cambridge Biomedical Research Centre), European Commission Framework 7 (through the EPIC-CVD award; HEALTH-F2-2012-279233), and the European Research Council (through an Advanced Investigator Award to JD; 268834). JD holds a BHF Professorship and NIHR Senior Investigator Award. A study website Funding for the EPIC-InterAct project was provided by the EU FP6 programme (grant number LSHM_CT_2006_037197). A study website includes a list that investigators have provided of funding agencies that have supported individual EPIC centres. A study website includes a list that investigators have provided of funding agencies that have supported individual cohorts of the ERFC contributing to the present consortium. This research has been conducted using the UK Biobank resource (application 21886). We thank Nicola Kerrison and Stephen Sharp (both from the University of Cambridge MRC Epidemiology Unit, Cambridge, UK) for the former's data management in the EPIC-InterAct subcohort and the latter's statistical input into development of the EPIC-CVD's analytical guidelines.

History

Citation

Lancet, 391 (10129), pp. 1513-1523

Author affiliation

/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Department of Health Sciences

Version

  • VoR (Version of Record)

Published in

Lancet

Publisher

Elsevier

issn

0140-6736

eissn

1474-547X

Acceptance date

2017-12-05

Copyright date

2018

Available date

2018-08-13

Publisher version

https://www.sciencedirect.com/science/article/pii/S014067361830134X?via=ihub

Language

en

Usage metrics

    University of Leicester Publications

    Categories

    No categories selected

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC